Rizatriptan: A Comprehensive Study Report on Its Pharmacology, Efficacy, and Clinical Applications in Migraine Therapy
-
BY Saundra Seaton
- July 24, 2026 5:06 am
- no comment
Rizatriptan is a selective serotonin (5-hydroxytryptamine; 5-HT) receptor agonist, specifically targeting the 5-HT1B and 5-HT1D receptor subtypes. It belongs to the triptan class of medications, which revolutionized the acute treatment of migraine headaches following the introduction of sumatriptan in the early 1990s. Approved by the U.S. Food and Drug Administration (FDA) in 1998, rizatriptan is […]